Abstract
In recent years, the role of pathology in breast cancer has changed dramatically. Currently, it no longer has a purely diagnostic role, based exclusively on morphology. Pathologists are now asked to provide some information about prognostic and predictive factors, in other words about the risk assessment and the choice of the best treatment, according to Veronesi’s paradigm: “from maximum tolerable treatment to minimum effective treatment”. These changes can be summarized in this way: in the past we were dealing with “what to treat”, now we are dealing with “how to treat”, aiming at dealing with “whom to treat”.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 22:1736–1747
Riedl CC, Pfarl G, Memarsadeghi M et al (2005) Lesion miss rates and false-negative rates for 1115 consecutive cases of stereotactically guided needle-localized open breast biopsy with long-term follow-up. Radiology 237:847–853
Niemann TH, Lucas JG, Marsh WL Jr (1996) To freeze or not to freeze. a comparison of methods for the handling of breast biopsies with no palpable abnormality. Am J Clin Pathol 106:225–228
Noguchi M, Minami M, Earashi M et al (1995) Pathologic assessment of surgical margins on frozen and permanent sections in breast conserving surgery. Breast Cancer 2:27–33
Morrow M (2009) Breast conservation and negative margins: how much is enough? Breast 18(Suppl 3):S84–S86
Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/college Of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795 Erratum in: (2010) J Clin Oncol 28:3543
Wolff AC, Hammond ME, Schwartz JN et al (2007) American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
Mirza AN, Mirza NQ, Vlastos G, Singletary SE (2002) Prognostic factors in node-negative breast cancer: A review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235:10–26
Tavassoli FA, Devilee P (eds) (2003) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, International Agency for Research on Cancer, Lyon
Viale G (2005) Histopathology of primary breast cancer. Breast 14:487–492
Veronesi U, Zurrida S, Goldhirsch A et al (2009) Breast cancer classification: time for a change. J Clin Oncol 15:2427–2428
Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874
Caliskan M, Gatti G, Sosnovskikh I et al (2008) Paget’s disease of the breast: the experience of the European institute of oncology and review of the literature. Breast Cancer Res Treat 112:513–521
Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 19:403–410
Sloane JP, Amendoeira I, Apostolikas N et al (1999) Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European commission working group on breast screening pathology. Virchows Arch 434:3–10
Veronesi U, Viale G, Paganelli G et al (2010) Sentinel lymph node biopsy in breast cancer. Ten-year results of a randomized controlled study. Ann Surg 251:595–600
Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM classification of malignant tumours, 7th edn. Wiley, Hoboken
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York
Arnone P, Zurrida S, Viale G et al (2010) The TNM classification of breast cancer: need for a change. Updates Surg 62:75–81
Regan MM, Viale G, Mastropasqua MG et al (2006) Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571–1581
Sauter G, Lee J, Barlett JM et al (2009) (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333
Perez EA, Roche PC, Jenkins RB et al (2002) HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148–154
Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women With endocrine-responsive breast cancer: results From Breast International Group Trial 1–98 comparing adjuvant tamoxifen with Letrozole. J Cin Oncol 26:5569–5575
Viale G, Regan MM, Mastropasqua MG et al (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207–212
Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. American Society of Clinical Oncology. J Clin Oncol 25:5287–5312
Dowsett M, Nielsen T, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: Recommendations form the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103:1656–1664
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Italia
About this chapter
Cite this chapter
Mastropasqua, M.G. (2013). Breast Cancer Pathology. In: Urban, C., Rietjens, M. (eds) Oncoplastic and Reconstructive Breast Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-2652-0_4
Download citation
DOI: https://doi.org/10.1007/978-88-470-2652-0_4
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2651-3
Online ISBN: 978-88-470-2652-0
eBook Packages: MedicineMedicine (R0)